India · Delayed Price · Currency is INR Sudeep Pharma Statistics
Total Valuation
Sudeep Pharma has a market cap or net worth of INR 125.58 billion. The enterprise value is 126.08 billion.
| Market Cap | 125.58B |
| Enterprise Value | 126.08B |
Important Dates
The last earnings date was Tuesday, August 4, 2026.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | Jul 23, 2026 |
Share Statistics
| Current Share Class | 112.95M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +3.47% |
| Shares Change (QoQ) | +1.22% |
| Owned by Insiders (%) | 37.13% |
| Owned by Institutions (%) | 14.55% |
| Float | 25.44M |
Valuation Ratios
The trailing PE ratio is 68.76 and the forward PE ratio is 62.41.
| PE Ratio | 68.76 |
| Forward PE | 62.41 |
| PS Ratio | 18.59 |
| PB Ratio | 13.98 |
| P/TBV Ratio | 15.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 180.55 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 69.03 |
| EV / Sales | 18.66 |
| EV / EBITDA | 54.22 |
| EV / EBIT | 58.00 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 0.65 |
| Debt / FCF | -9.51 |
| Interest Coverage | 29.16 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 17.94% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 12.87M |
| Profits Per Employee | 3.48M |
| Employee Count | 525 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Sudeep Pharma has paid 546.93 million in taxes.
| Income Tax | 546.93M |
| Effective Tax Rate | 22.95% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 902.42 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 69.51 |
| Average Volume (20 Days) | 28,177 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sudeep Pharma had revenue of INR 6.76 billion and earned 1.83 billion in profits. Earnings per share was 16.21.
| Revenue | 6.76B |
| Gross Profit | 4.30B |
| Operating Income | 2.17B |
| Pretax Income | 2.38B |
| Net Income | 1.83B |
| EBITDA | 2.32B |
| EBIT | 2.17B |
| Earnings Per Share (EPS) | 16.21 |
Balance Sheet
The company has 1.15 billion in cash and 1.50 billion in debt, with a net cash position of -357.77 million.
| Cash & Cash Equivalents | 1.15B |
| Total Debt | 1.50B |
| Net Cash | -357.77M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 8.98B |
| Book Value Per Share | 78.21 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 695.53 million and capital expenditures -853.78 million, giving a free cash flow of -158.25 million.
| Operating Cash Flow | 695.53M |
| Capital Expenditures | -853.78M |
| Depreciation & Amortization | 142.16M |
| Net Borrowing | 102.91M |
| Free Cash Flow | -158.25M |
| FCF Per Share | n/a |
Margins
Gross margin is 63.71%, with operating and profit margins of 32.18% and 27.03%.
| Gross Margin | 63.71% |
| Operating Margin | 32.18% |
| Pretax Margin | 35.27% |
| Profit Margin | 27.03% |
| EBITDA Margin | 34.28% |
| EBIT Margin | 32.18% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 0.14%.
| Dividend Per Share | 1.50 |
| Dividend Yield | 0.14% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.47% |
| Shareholder Yield | -3.34% |
| Earnings Yield | 1.45% |
| FCF Yield | -0.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Sudeep Pharma is 777.50, which is -30.02% lower than the current price. The consensus rating is "Sell".
| Price Target | 777.50 |
| Price Target Difference | -30.02% |
| Analyst Consensus | Sell |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |